Winner’s lead therapy targets Parkinson’s disease; platform addresses 6,000+ genetic disorders

获奖者的主导疗法针对帕金森病；平台解决6000多种遗传疾病。

Neoclease gains access to Merck’s technologies and expert support to scale its AI-designed gene-editing platform

Neoclease获得访问默克技术及专家支持，以扩展其AI设计的基因编辑平台。

Merck has awarded 40+ startups globally through the Advance Biotech Grant since 2014

自2014年以来，默克通过“Advance Biotech Grant”已向全球40多家初创企业颁奖。

Merck, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson’s disease.

默克公司，一家领先的科技企业，今天宣布Neoclease荣获2025年北美先进生物技术奖。这家总部位于波士顿的生物技术初创公司开发用于帕金森病的AI设计基因编辑疗法。

“We’re committed to empowering biotech innovators who are advancing transformative modalities like gene editing,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck. “By combining Neoclease’s AI-designed gene-editing platform with our technologies, regulatory expertise, and process support, we aim to help accelerate new treatments that minimize side effects and maximize effectiveness for patients.”.

“我们致力于赋能那些推动基因编辑等变革性技术的生物技术创新者，”默克生命科学业务部工艺解决方案负责人塞巴斯蒂安·阿拉纳表示。“通过将 Neoclease 的人工智能设计基因编辑平台与我们的技术、监管专业知识和工艺支持相结合，我们旨在帮助加速开发出能够最大限度减少副作用并最大化提高患者疗效的新疗法。”

Neoclease’s platform combines generative AI and synthetic biology to develop next-generation, precision gene-editing therapies. Neoclease’s lead candidate, NCX-L2, is designed to slow or halt the progression of Parkinson’s disease – a condition that currently has no disease-modifying treatments. More broadly, Neoclease’s approach has the potential to address more than 6,000 monogenic diseases by targeting the root causes of illness rather than only managing symptoms..

Neoclease的平台结合了生成式人工智能和合成生物学，开发下一代精准基因编辑疗法。Neoclease的领先候选药物NCX-L2旨在减缓或阻止帕金森病的进展——这是一种目前尚无疾病修饰治疗手段的疾病。更广泛地说，Neoclease的方法有望通过针对疾病的根源而非仅仅缓解症状，来应对超过6000种单基因疾病。

As part of the grant, Neoclease will receive access to Merck’s products, technologies, and contract testing services, as well as expert consultation and training through the M Lab™ Collaboration Center and Emprove

作为资助的一部分，Neoclease 将获得默克公司产品、技术以及合同测试服务的访问权限，并通过 M Lab™ 协作中心和 Emprove 获得专家咨询和培训。

®

®

program. M Lab™ Collaboration Centers offer hands-on technical solutions and process optimization, while the Emprove

计划。M Lab™合作中心提供实际操作的技术解决方案和工艺优化，而Emprove

®

®

Program simplifies risk management and regulatory compliance through quality products, detailed documentation, and dedicated support. These resources will support Neoclease in scaling its processes, optimizing manufacturing, and navigating regulatory requirements.

该程序通过优质产品、详细文档和专门支持简化了风险管理和合规性。这些资源将支持Neoclease扩大其流程、优化制造并应对法规要求。

The Advance Biotech Grant Program, launched in 2014, reflects Merck’s ongoing commitment to supporting early-stage biotech companies developing innovative therapies for patients. To date, more than 40 companies worldwide have received grants and technical support across a wide range of therapeutic areas including cancer, neurological diseases, and cardiovascular disorders.

2014年启动的Advance Biotech资助计划反映了默克公司持续致力于支持为患者开发创新疗法的早期生物技术公司。迄今为止，全球已有40多家公司获得资助和技术支持，涵盖包括癌症、神经系统疾病和心血管疾病在内的广泛治疗领域。

Merck will continue this global effort with upcoming grant awards in Asia-Pacific (October) and Europe, the Middle East, and Africa (November)..

默克将继续在全球范围内开展这项工作，并将在亚太地区（10月）和欧洲、中东及非洲（11月）颁发即将的拨款奖项。